$-0.01
(Market cap
$14 Mln
Revenue (TTM)
$29 Mln
P/E Ratio
--
P/B Ratio
0.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.2
-
Debt to Equity
0.2
-
Book Value
$8.9
-
EPS
$-5.3
-
Face value
--
-
Shares outstanding
11,092,000
8 Years Aggregate
CFO
$-458.55 Mln
EBITDA
$-457.62 Mln
Net Profit
$-569.21 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Bionano Genomics (BNGO)
| -18.3 | 10.6 | 14.7 | -67.4 | -85.4 | -78.7 | -- |
|
BSE Sensex*
| -11.0 | -1.9 | -8.7 | -7.1 | 6.7 | 9.1 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Bionano Genomics (BNGO)
| -91.2 | -84.5 | -87.1 | -51.2 | -2.9 | 148.4 | -76.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Bionano Genomics (BNGO)
|
1.3 | 14.1 | 28.5 | -26.4 | -116.9 | -66.2 | -- | 0.3 |
| 7.9 | 5,441.6 | 6,552.2 | -551.4 | -4.3 | -9.9 | -- | 1.0 | |
| 255.5 | 6,838.7 | 2,589.9 | 168.8 | 21.4 | 2.5 | 42.5 | 1.0 | |
| 43.9 | 6,586.8 | 3,458.5 | -10.3 | 1.9 | -0.5 | -- | 2.7 | |
| 137.3 | 7,950.8 | 551.4 | -189.3 | -15.6 | -26.3 | -- | 11.7 | |
| 96.5 | 6,124.5 | 1,546.2 | 279.0 | 15.0 | 23.9 | 22.5 | 5.0 | |
| 178.4 | 9,347.9 | 1,558.5 | 76.3 | 19.1 | 9.5 | 44.1 | 11.8 | |
| 322.6 | 12,653.3 | 1,454.3 | 171.1 | 11.1 | 12.1 | 74.1 | 8.6 | |
| 107.0 | 6,538.2 | 763.3 | 51.4 | 11.6 | 2.5 | 127.4 | 3.3 | |
| 29.8 | 12,420.6 | 6,178.4 | 626.5 | 13.0 | 11.9 | 20.3 | 2.4 |
Shareholding Pattern
View DetailsAbout Bionano Genomics (BNGO)
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that... enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California. Address: 9540 Towne Centre Drive, San Diego, CA, United States, 92121 Read more
-
President, CEO, Secretary & Director
Dr. Robert Erik Holmlin M.B.A., Ph.D.
-
President, CEO, Secretary & Director
Dr. Robert Erik Holmlin M.B.A., Ph.D.
-
Headquarters
San Diego, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Bionano Genomics (BNGO)
What is the current share price of Bionano Genomics Inc (BNGO) Today?
The share price of Bionano Genomics Inc (BNGO) is $1.25 (NASDAQ) as of 13-May-2026 16:27 EDT. Bionano Genomics Inc (BNGO) has given a return of -85.35% in the last 3 years.
What is the current PB & PE ratio of Bionano Genomics Inc (BNGO)?
Since, TTM earnings of Bionano Genomics Inc (BNGO) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-0.29
|
0.17
|
|
2024
|
0.00
|
0.01
|
|
2023
|
-0.01
|
0.02
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
What is the 52 Week High and Low of Bionano Genomics Inc (BNGO)?
The 52-week high and low of Bionano Genomics Inc (BNGO) are Rs 5.08 and Rs 1.06 as of 14-May-2026.
What is the market cap of Bionano Genomics Inc (BNGO)?
Bionano Genomics Inc (BNGO) has a market capitalisation of $ 14 Mln as on 12-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Bionano Genomics Inc (BNGO)?
Before investing in Bionano Genomics Inc (BNGO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.